Canine Muscular Dystrophy
Delve into the crucial role of canine models in advancing treatments for Duchenne Muscular Dystrophy (DMD), a devastating, X-linked muscle-wasting disease. This summary covers the latest findings across therapeutic strategies, diagnostic biomarkers, and underlying disease mechanisms derived from sophisticated dog models like the Golden Retriever Muscular Dystrophy (GRMD), Canine X-linked Muscular Dystrophy in Japan (CXMDj), and the DE50-MD dogs.Gene Therapy Breakthroughs and Treatment TargetsResearch in the DE50-MD model, which mimics a common human mutational hotspot, demonstrates remarkable success in gene editing. Systemic intravenous delivery of Adeno-Associated Virus serotype nine (AAV9) encoding CRISPR-Cas9 components successfully restored Dystrophin protein widely throughout the body. The high dose resulted in up to ninety-two percent of wild-type Dystrophin levels in the heart and significant restoration in skeletal muscles, such as seventy percent in the cranial tibialis and fifty-eight percent in the diaphragm. Histologically, treated muscles showed improvement with reduced necrosis and fibrosis.Beyond gene correction, metabolic strategies offer therapeutic potential. GRMD dogs exhibit significantly reduced Nicotinamide Adenine Dinucleotide NAD content in striated muscles, an energy cofactor depleted due to altered synthesis and increased consumption by poly(ADP-ribose) polymerases (PARPs). Short-term oral supplementation with nicotinamide successfully boosted muscle NDA levels and led to a mild beneficial effect, including a stabilization trend in clinical scores and a significant improvement in the maximal inspiratory/expiratory flows ratio, suggesting modest stabilization of respiratory function.Advanced Diagnostics and Objective BiomarkersObjective measures are crucial for quantifying therapeutic efficacy. The gold standard for assessing skeletal muscle function in preclinical trials is the Eccentric Contraction Decrement (ECD) protocol, which measures the rapid loss of force (torque decrement) when dystrophic muscle lengthens under contraction. Clinically, Dystrophin deficient dogs often present with markedly and persistently elevated Creatine Kinase (CK) levels. Symptoms can include macroglossia (enlarged tongue), reduced mandibular extension, dysphagia (swallowing difficulty), and regurgitation. Radiographic signs often include diaphragmatic thickening and an axial gastro-esophageal hiatal hernia. Clinicians must note that volatile inhalant anesthetic agents can trigger hyperkalemic cardiac arrest due to membrane instability in Dystrophin deficient muscle fibers; therefore, total intravenous anesthesia is recommended. Referenced Articles:• Replenishing NAD+ content reduces aspects of striated muscle disease in a dog model of Duchenne muscular dystrophy• Digital Outcome Measures for Gait and Spontaneous Locomotor Activity in Dystrophic Dogs• Cardio-Physiological Evaluations in a Dog Model with Duchenne Muscular Dystrophy• Canine Model of Duchenne Muscular Dystrophy• Exploring Desmin as a Potential Modifier in Duchenne Muscular Dystrophy–Associated Cardiomyopathy• Congenital muscular dystrophy in a dog with a LAMA2 gene deletion• Radiographic, MRI, and CT findings in a young dog with Becker-like muscular dystrophy• Longitudinal assessment of skeletal muscle functional mechanics in the DE50-MD dog model of Duchenne muscular dystrophy• Dystrophin-Deficient Muscular Dystrophy in a Family of Shiba Inu Dogs with a Complex Deletion Encompassing DMD Exon 5• Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy• Lymphatic dysfunction is linked to disease pathogenesis in Duchenne muscular dystrophy animal models
